One World Products, Inc.

OTCPK:OWPC Stock Report

Market Cap: US$2.8m

One World Products Valuation

Is OWPC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OWPC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OWPC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OWPC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OWPC?

Key metric: As OWPC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for OWPC. This is calculated by dividing OWPC's market cap by their current book value.
What is OWPC's PB Ratio?
PB Ratio-0.3x
Book-US$9.81m
Market CapUS$2.75m

Price to Book Ratio vs Peers

How does OWPC's PB Ratio compare to its peers?

The above table shows the PB ratio for OWPC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.5x
PTPI Petros Pharmaceuticals
0.9x33.6%US$2.9m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.9m
YCBD cbdMD
0.6x107.9%US$1.8m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.4m
OWPC One World Products
n/an/aUS$2.8m

Price-To-Book vs Peers: OWPC has negative equity and a Price-To-Book Ratio (-0.3x) compared to the peer average (0.5x).

Price to Book Ratio vs Industry

How does OWPC's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.02m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.86m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.93m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.45m
OWPC is unprofitableIndustry Avg. 1.7xNo. of Companies29PB01.22.43.64.86+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: OWPC has negative equity and a Price-To-Book Ratio (-0.3x) compared to the US Pharmaceuticals industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is OWPC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OWPC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-0.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OWPC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

7D

5.2%

1Y

-4.6%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%